Integration of cancer genomics with treatment selection

From the genome to predictive biomarkers

Authors

  • Thomas J. Ow MD, MS,

    1. Department of Otorhinolaryngology-Head and Neck Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York
    2. Department of Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York
    Search for more papers by this author
  • Vlad C. Sandulache MD, PhD,

    1. Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas
    Search for more papers by this author
  • Heath D. Skinner MD, PhD,

    1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for more papers by this author
  • Jeffrey N. Myers MD, PhD

    Corresponding author
    1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas
    • Corresponding author: Jeffrey N. Myers, MD, PhD, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1445, Room FCT10.6028, Houston, TX 77030-4009; Fax: (713) 794-4662; jmyers@mdanderson.org

    Search for more papers by this author

Abstract

The field of cancer genomics is rapidly advancing as new technology provides detailed genetic and epigenetic profiling of human cancers. The amount of new data available describing the genetic make-up of tumors is paralleled by rapid advances in drug discovery and molecular therapy currently under investigation to treat these diseases. This review summarizes the challenges and approaches associated with the integration of genomic data into the development of new biomarkers in the management of cancer. Cancer 2013;119:3914–3928. © 2013 American Cancer Society.

Ancillary